Lutris Pharma
Tel Aviv-yafo
About Lutris Pharma
Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness. The company develops the topical B-Raf inhibitor LUT014, a proprietary small molecule that allows administration of epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects. Lutris Pharma was established in 2015 and is based in Tel Aviv-yafo, Israel.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $35.0M
- Last round: Series Unknown (Jan 2025)
- Website: lutris-pharma.com
Industries & Categories
Biotechnology, First Aid, Health Care, Wellness
Social Profiles
Canonical: https://fsome.com/organization/lutris-pharma-128126 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.